ArticlePharmacoEconomics - open2023

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.

Ryan Pulleyblank et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.